Aquinox Pharmaceuticals Inc. (NASDAQ:AQXP) traded up 2.6% on Tuesday . The company traded as high as $9.49 and last traded at $9.38, with a volume of 103,165 shares. The stock had previously closed at $9.14.

A number of equities research analysts have recently weighed in on the company. Zacks Investment Research downgraded Aquinox Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Tuesday. Needham & Company LLC assumed coverage on Aquinox Pharmaceuticals in a research report on Thursday, May 12th. They set a “buy” rating and a $25.00 target price for the company. Canaccord Genuity set a $22.00 target price on Aquinox Pharmaceuticals and gave the stock a “buy” rating in a research report on Thursday, July 21st. Finally, Jefferies Group upped their price objective on Aquinox Pharmaceuticals from $7.00 to $9.00 and gave the company a “hold” rating in a report on Friday. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and five have assigned a buy rating to the stock. Aquinox Pharmaceuticals has a consensus rating of “Buy” and a consensus price target of $19.86.

The stock’s 50-day moving average price is $7.60 and its 200-day moving average price is $8.51. The firm’s market capitalization is $161.96 million.

Aquinox Pharmaceuticals (NASDAQ:AQXP) last issued its earnings results on Thursday, August 4th. The company reported ($0.63) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.41) by $0.22. Equities analysts predict that Aquinox Pharmaceuticals Inc. will post ($2.13) EPS for the current year.

Aquinox Pharmaceuticals, Inc is a clinical-stage pharmaceutical company discovering and developing targeted therapeutics in disease areas of inflammation and immuno-oncology. The Company operates in the segment of identification and development of therapeutics in disease areas of inflammation and immuno-oncology.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.